Pancreatic Cancer

First-line IMM-1-104 combined with modified gemcitabine/nab-paclitaxel elicited both partial and complete responses in patients with pancreatic cancer.

Males harboring BRCA1/2 pathologic variants have a higher risk of developing select cancers but are less likely to undergo genetic testing.

The FDA granted fast track designation to IMM-1-104 for first-line pancreatic ductal adenocarcinoma.

Two late-stage trials investigating the efficacy and safety of pamrevlumab in pancreatic cancer failed to meet their primary end points of OS.

Eileen M. O'Reilly, MD, details how RAS-directed therapy could potentially change the pancreatic cancer landscape and highlights updated data in the space.

S. Lindsey Davis, MD, highlights data with the mTOR inhibitor sapanisertib and Aurora A kinase inhibitor alisertib in patients with solid tumors.

Mitazalimab plus mFOLFIRINOX yielded early efficacy signals and a manageable safety profile for the frontline treatment of patients with mPDAC.

MPO may be a predictive biomarker for survival for treatment with CM24, nivolumab, and chemotherapy in second-line pancreatic ductal adenocarcinoma.

Frontline mitazalimab plus mFOLFIRINOX generated an OS benefit and prolonged DOR in patients with metastatic pancreatic ductal adenocarcinoma.

XB2001 plus chemotherapy improved safety and was tied to a trend toward improved overall survival in pretreated advanced pancreatic cancer.

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the benefits and challenges of DNA and RNA testing for NRG1 fusions in patients with pancreatic cancer.

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses prognosis and rarity of patients with NRG1 fusion–positive pancreatic cancer.

The FDA granted fast track designation to IBI343 monotherapy for relapsed/refractory advanced unresectable or metastatic pancreatic ductal adenocarcinoma.

Brandon Huffman, MD, discusses an ongoing phase 2 trial evaluating azenosertib plus gemcitabine in advanced pancreatic cancer.

Suneel Kamath, MD, discusses tumor microbiome differences between early-onset and average-onset pancreatic adenocarcinoma.

Zyed Nabeel Zafar, MD, MPH, explores the nuances of postoperative considerations in pancreatic cancer treatment.

Pitavastatin, an FDA-approved statin, may inhibit pathways that contribute to IL-33 production, which has been shown to contribute to cancer development.

Kian-Huat Lim, MD, PhD, discusses the importance of multidisciplinary collaboration when diagnosing and treating patients with pancreatic cancer.

VCN-01 plus gemcitabine and nab-paclitaxel has received fast track designation from the FDA in metastatic pancreatic adenocarcinoma.

The FDA has granted orphan drug designation to azeliragon as a potential therapeutic option for patients with pancreatic cancer.

Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being further investigated.

Capecitabine or XELOX failed to improve OS at 2 years vs fluorouracil/cisplatin as DCRT in inoperable locally advanced esophageal squamous cell carcinoma.

Kian-Huat Lim, MD, PhD, discusses the role of multidisciplinary collaboration and clinical trials in the treatment of pancreatic cancer.

Kian-Huat Lim, MD, PhD, discusses the current treatment landscape for metastatic pancreatic cancer.

The PRECEDE study demonstrated the feasibility of a large-scale early detection and prevention program for pancreatic cancer.